ceritinib and Central-Nervous-System-Neoplasms

ceritinib has been researched along with Central-Nervous-System-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for ceritinib and Central-Nervous-System-Neoplasms

Article	Year
An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 06-13, Volume: 28, Issue:12 Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506. Topics: Anaplastic Lymphoma Kinase; Brain; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Central Nervous System Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones	2022

Article

Year

An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 06-13, Volume: 28, Issue:12

Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506.

Topics: Anaplastic Lymphoma Kinase; Brain; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Central Nervous System Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2022